King Pharmaceuticals, Inc. / Alpharma Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed by the Registrant
o
Filed by a Party other than the Registrant
x
Check the appropriate box:
|
|
|
o Preliminary
Proxy Statement |
|
|
o Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
o Definitive
Proxy Statement
|
o Definitive
Additional Materials
|
x Soliciting
Material Pursuant to §240.14a-12
|
ALPHARMA INC.
(Name of Registrant as Specified In Its Charter)
KING PHARMACEUTICALS, INC.
(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
x |
No fee required.
|
|
o |
Fee computed on table below per Exchange Act
Rules 14a-6(i)(4) and 0-11.
|
|
|
(1) |
Title of each class of securities to which
transaction applies: N/A
|
|
|
(2) |
Aggregate number of securities to which
transaction applies: N/A
|
|
|
(3) |
Per unit price or other underlying value of
transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined): N/A
|
|
|
(4) |
Proposed maximum aggregate value of
transaction: N/A
|
|
|
o |
Fee paid previously with preliminary materials.
|
|
o |
Check box if any part of the fee is offset as
provided by Exchange Act Rule 0-11(a)(2) and identify the
filing for which the offsetting fee was paid previously.
Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
|
|
|
(1) |
Amount Previously Paid: N/A
|
|
|
(2) |
Form, Schedule or Registration Statement No.: N/A
|
Following
is the text of an e-mail sent to employees of King Pharmaceuticals,
Inc. on August
22, 2008:
Dear Fellow Employee:
I have some important news to share. This morning, our company publicly submitted a proposal to
acquire Alpharma Inc. in an all cash transaction. I believe that Alpharma represents an excellent
strategic fit with King, as our combined strengths would create a stronger platform to deliver
innovative products to patients, prescribers and customers. This combination would provide
increased capabilities and resources to successfully launch new products and deliver pipeline
opportunities.
Furthermore, we are convinced that this compelling combination would create a strong foundation for
sustainable, long term growth enabling King to better address the changes facing the healthcare
industry. In addition to Alpharmas growing pharmaceutical business, Alpharma also has a global
Animal Health Division which is a leading livestock feed additives business. As with our Meridian
business, Alpharmas Animal Health Division would provide King with an additional source of steady
cash flow.
My hope is that we can move expeditiously and consummate this transaction by the close of 2008. A
copy of the press release, including the letter we submitted directly to Alpharma explaining the
proposed transaction, can be found on King Connects.
Please do not let this exciting news distract you from your day to day responsibilities which are
critical to the continued success of our company. Throughout this process, it is imperative that
all of you remain focused on our business objectives. I cannot stress enough the importance of
refraining from speculative communications, whether verbal or through email. In the event that you
are contacted by members of the media or financial community regarding this proposed transaction,
please refer all inquiries directly to Corporate Affairs at (423) 989-8711.
We will make every effort to keep you informed throughout this process, keeping in mind that there
are certain legal and regulatory requirements that we must follow. I know that I can count on you
to maintain the same high level of professionalism that has made King an industry leader in the
markets we serve.
On behalf of our Board of Directors and senior leadership team, I thank you for your continued
focus, commitment, dedication and valued contributions to our business.
Brian A. Markison
Chairman, President and Chief Executive Officer
Forward-looking Statements
This document contains forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995 (the Act). King Pharmaceuticals, Inc. (King) disclaims any intent or
obligation to update these forward-looking statements, and claims the protection of the Safe Harbor
for forward-looking statements contained in the Act. All statements contained in this document
that are not clearly historical in nature or that necessarily depend on future events are
forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar
expressions are generally intended to identify forward-looking statements. Such statements are
based on managements current expectations, but actual results may differ materially due to various
factors such as Kings ability to achieve the synergies and value creation contemplated by the
proposed transaction; Kings ability to promptly and effectively integrate the businesses of
Alpharma Inc. (Alpharma) and King and any necessary actions to obtain required regulatory
approvals; the potential of Kings branded pharmaceutical products; expectations regarding the
enforceability and effectiveness of product-related patents; expected trends and projections with
respect to particular products, reportable segment and income and expense line items; the adequacy
of Kings liquidity and capital resources; anticipated capital expenditures; the acceptance,
priority review or approval of certain New Drug Applications; the development, approval and
successful commercialization of certain products; the successful execution of growth and
restructuring strategies, including Kings accelerated strategic shift; anticipated developments
and expansions of Kings business; plans for the manufacture of some of Kings products; the
potential costs, outcomes and timing of research, clinical trials and other development activities
involving pharmaceutical products; the development of product line extensions; the expected timing
of the initial marketing of certain products; products developed, acquired or in-licensed that may
be commercialized; Kings intent, beliefs or current expectations, primarily with respect to future
operating performance; expectations regarding sales growth, gross margins, manufacturing
productivity, capital expenditures and effective tax rates; expectations regarding the outcome of
various pending legal proceedings; expectations regarding Kings financial condition and liquidity
as well as future cash flows and earnings; expectations regarding the ability to liquidate Kings
holdings of auction rate securities and the temporary nature of the unrealized losses recorded in
connection with these securities. Forward-looking statements involve risks and uncertainties. For
further information regarding these and other risks related to Kings business, investors should
consult Kings most recent Annual Report on Form 10-K for the year ended December 31, 2007 and
Kings quarterly reports on Form 10-Q and other documents filed by King with the U.S. Securities
and Exchange Commission (SEC).
Important Additional Information
This document is not a substitute for any disclosure documents, including any proxy statement,
King may file with the SEC and send to Alpharma stockholders in connection with any business
combination transaction with Alpharma or any solicitation of the stockholders of Alpharma.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ ANY SUCH DISCLOSURE DOCUMENTS FILED WITH THE SEC
CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. INVESTORS AND SECURITY HOLDERS WILL BE ABLE TO OBTAIN FREE COPIES OF ANY SUCH
DOCUMENTS FILED WITH THE SEC BY KING AT WWW.KINGPHARM.COM AND THROUGH THE WEB SITE MAINTAINED BY
THE SEC AT WWW.SEC.GOV. FREE COPIES OF ANY SUCH DOCUMENTS CAN ALSO BE OBTAINED BY DIRECTING A
REQUEST TO KINGS PROXY SOLICITOR, INNISFREE M&A INCORPORATED AT (877) 687-1875.
King and certain of its directors and executive officers and other persons may be deemed to be
participants in the solicitation of proxies in respect of any business combination transaction or
solicitation of the stockholders of Alpharma. As of the date of this document, King is the
beneficial owner of 10 shares of Alpharma Class A Common Stock. INFORMATION REGARDING KINGS
DIRECTORS AND EXECUTIVE OFFICERS IS AVAILABLE IN ITS ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED
DECEMBER 31, 2007, WHICH WAS FILED WITH THE SEC ON FEBRUARY 29, 2008, AND ITS PROXY STATEMENT FOR
ITS 2008 ANNUAL MEETING OF STOCKHOLDERS, WHICH WAS FILED WITH THE SEC ON APRIL 15, 2008. OTHER
INFORMATION REGARDING THE PARTICIPANTS IN A PROXY SOLICITATION AND A DESCRIPTION OF THEIR DIRECT
AND INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE, WILL BE CONTAINED IN THE DISCLOSURE
DOCUMENTS, INCLUDING ANY PROXY STATEMENT, TO BE FILED BY KING WITH THE SEC WHEN THEY BECOME
AVAILABLE.